Home › NDC Lookup › RxCUI directory › RxCUI 2286607

Bimatoprost 0.01 MG Drug Implant [Durysta] — RxCUI 2286607

RxNorm drug concept · Semantic branded drug
RxCUI 2286607 Semantic branded drug · SBD ● Current RxNorm concept 1 FDA product 2 package NDCs Snapshot Jul 14, 2026

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2286607
Official nameBimatoprost 0.01 MG Drug Implant [Durysta]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asDurysta 10 MCG Drug Implant; DURYSTA 10 MCG Intracameral Implant
FDA products mapped1
Package NDCs mapped2
Reported Medicaid activity (SDUD)501 prescriptions · 10 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Bimatoprost Ophthalmic: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Bimatoprost ophthalmic 0.03% is used to grow longer, thicker and darker eyelashes if you have hypotrichosis, meaning sparse lashes. Lumigan is a related bimatoprost eye drop used f...
  • Do it once at night on a clean face with makeup and contacts out. Put one drop on the sterile applicator and brush it along the upper lid at the base of the lashes. Blot extra, and...
  • No. Extra applications will not increase growth. If you stop, your lashes are expected to return to how they were before treatment.
  • Will using more make my lashes grow more?
📖 Read our full Bimatoprost Ophthalmic guide →

🕸️ Concept Web — How Bimatoprost 0.01 MG Drug Implant [Durysta] Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Bimatoprost 0.01 MG Drug Implant [Durysta] RxCUI 2286607

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Bimatoprost 283810
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Durysta 2286603
  3. Dose forms 6

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Bimatoprost Drug Implant 2286601
    • Bimatoprost Drug Implant Product 2286600
    • Bimatoprost Drug Implant [Durysta] 2286605
    • Durysta Drug Implant Product 2286606
    • Drug Implant 657710
    • Drug Implant Product 1151136
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 11 of 11 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Bimatoprost 0.01 MG Drug Implant SCD · 2286602
  • Bimatoprost 0.01 MG SCDC · 2286599
  • Bimatoprost Drug Implant SCDF · 2286601
  • Bimatoprost Drug Implant Product SCDG · 2286600

Brand-Name Concepts

  • Bimatoprost 0.01 MG [Durysta] SBDC · 2286604
  • Bimatoprost Drug Implant [Durysta] SBDF · 2286605
  • Durysta Drug Implant Product SBDG · 2286606
  • Durysta BN · 2286603

📦 FDA Products & Package NDCs

1 product · 2 package NDCs
2 package NDCs map to RxCUI 2286607 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00023-9652-01 1 IMPLANT in 1 POUCH (0023-9652-01) DURYSTA Allergan, Inc. 2020-03-04
00023-9652-03 1 IMPLANT in 1 POUCH (0023-9652-03) DURYSTA Allergan, Inc. 2020-03-04
Observed labelers: Allergan, Inc. (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🧾 Billing Codes (HCPCS)

Medical billing codes (HCPCS "J-codes") that connect to this concept's packages — used mostly when a clinic or hospital bills for a drug it administers. Each code links to its full billing page.
CodeDescriptorMapped packagesSources
J7351 Inj bimatoprost itc imp1mcg 1 CMS
⚠ A crosswalk is not coverage: an NDC↔HCPCS mapping does not guarantee any payer covers or pays the code. Always verify the current payer policy before billing.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.